Beranda › Kanker Gastrointestinal › Michigan
Uji klinis Kanker Gastrointestinal di Michigan
13 studi untuk Kanker Gastrointestinal mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
- dan 50 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07283939Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Chelsea Hospital, Chelsea
- Trinity Health Saint Mary Mercy Livonia Hospital, Livonia
- dan 1 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07215624A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- The Cancer & Hematology Centers, Big Rapids
- The Cancer & Hematology Centers, Grand Rapids
- The Cancer & Hematology Centers, Grand Rapids
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222800A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
- Start Midwest, Grand Rapids
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06663319A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Ann Arbor
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07218926Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
- START Midwest, Grand Rapids
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07539311A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
- USA02-0, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT07263594A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- University of Michigan, Ann Arbor
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT07020221Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Henry Ford Cancer-Detroit, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Des 2025 · NCT06065371Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- Karmanos Cancer Institute, Detroit
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2025 · NCT06908629Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.